TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.
MINNEAPOLIS , June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More than 160 antibody therapies against nearly 100 targets and range of diseases have been approved worldwide.
ST. PAUL, Minn. , June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India.
![]() TE1 1 month ago | Other | €0.07 Per Share |
![]() TE1 4 months ago | Other | €0.07 Per Share |
![]() TE1 7 months ago | Other | €0.07 Per Share |
![]() TE1 10 months ago | Other | €0.07 Per Share |
![]() TE1 10 May 2024 | Other | €0.07 Per Share |
13 Aug 2025 (In 1 month) Date | | 0.5 Cons. EPS | - EPS |
5 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
29 Apr 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | - Cons. EPS | - EPS |
![]() TE1 1 month ago | Other | €0.07 Per Share |
![]() TE1 4 months ago | Other | €0.07 Per Share |
![]() TE1 7 months ago | Other | €0.07 Per Share |
![]() TE1 10 months ago | Other | €0.07 Per Share |
![]() TE1 10 May 2024 | Other | €0.07 Per Share |
13 Aug 2025 (In 1 month) Date | | 0.5 Cons. EPS | - EPS |
5 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
29 Apr 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Kim Kelderman CEO | XSTU Exchange | US09073M1045 ISIN |
US Country | 3,100 Employees | 19 May 2025 Last Dividend | 30 Nov 2022 Last Split | 9 Feb 1989 IPO Date |
Bio-Techne Corporation operates at the forefront of the life science sector, providing a comprehensive range of products and services crucial for research, clinical diagnostics, and therapeutic development. With a global footprint, the company serves a diverse clientele spread across the United States, the United Kingdom, rest of Europe, Middle East, Africa, Greater China, and the rest of the Asia-Pacific region. Bio-Techne is structured into two main operational segments: Protein Sciences, and Diagnostics and Genomics, each addressing different needs within the life sciences and diagnostics sectors. Originally established in 1976 under the name Techne Corporation, the organization underwent a rebranding to Bio-Techne Corporation in November 2014 and is based in Minneapolis, Minnesota. This strategic evolution reflects its broadened focus beyond its initial scope, signaling its expansion into a comprehensive suite of technologies and services catering to the dynamic requirements of biological research and clinical diagnostics.
Bio-Techne Corporation distinguishes itself through its broad portfolio of products and services across two main segments: